Vaping nicotine before THC changes how much gets into your blood
NCT ID NCT06334016
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study looks at how using nicotine vapes before or after THC vapes changes the amount of THC that enters the bloodstream. Researchers will compare THC levels and effects in 60 adults who regularly use both products. The goal is to understand safety and how these products work together.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 21 years of age; (self-reported on screening, verified at study visit). * Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported). * Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported). * Report use of THC vaping liquids at least weekly (4x/month); (self-reported). * Daily use of nicotine vaping products containing 5% nicotine for at least 3 months prior to enrollment; (self-reported). * Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures. * Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products. * Negative THC saliva test (NarcoCheck Ref#: NCE-S-THC-1), detection level 1-3 on urinary THCA rapid test (NarcoCheck® THC PreDosage), and illicit drug screen negative for all drugs except THC (NarcoCheck® Évolutive®). * Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 7 days prior to each session. * Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure. Exclusion Criteria: * Detection level 4-5 (\> 300 ng/mL) on urinary THCA rapid test (NarcoCheck® THC PreDosage Ref#: DOA-M03-9B) and a positive result on THC saliva test (NarcoCheck Ref#: NCE-S-THC-1). * Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted * Illegal or non-prescription drug use/alcohol substance use disorder (SUD) within the past year; (self-reported). * Report 2 or more drinking occasions/week with 4 or more drinks/occasion; (self-reported). * Report of daily cigarette use; (self-reported). * Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported). * Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported). * Current or prior cancer diagnosis. * Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test). * Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported). * Unwilling or unable to follow protocol requirements. * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation. * The following special populations will be excluded: * Cognitively impaired adults/adults with impaired decision-making capacity * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis dependence are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cannabis and driving: study probes how chronic use blurs vision of moving objects
- Scientists use brain scans and phones to decode addiction
- Brain scans reveal what happens when cannabis users with psychosis go cold turkey
- Scientists scan brains to uncover cannabinoid receptor secrets in mental illness and addiction
- Weight-Loss drug semaglutide tested as cannabis craving cure
- Teen brain scans may predict cannabis treatment success